Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody cocktail aims to tame ulcerative colitis for good

NCT ID NCT07652294

ENROLLING_BY_INVITATION Disease control Sponsor: Spyre Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 9 times

Summary

This study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SPY001, SPY002, SPY003 (long-acting antibodies)
What this could lead to
If successful, this could point toward a new long-term treatment option for ulcerative colitis that may help control the disease with fewer doses.
What could go wrong
This is an early-phase extension study, so results are preliminary. The antibodies may not prove effective or safe over the long term, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colitis inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS COLITIS, ULCERATIVE INFLAMMATORY BOWEL DISEASES ULCERATIVE COLITIS

Contacts and locations

Locations

  • Site 353

    Wŏnju, Gangwon-do, 26426, South Korea

  • Site 356

    Seoul, 03312, South Korea

  • Site 396

    Taichung, 404327, Taiwan

  • Site 531

    Brno, 615 00, Czechia

  • Site 583

    Tbilisi, 0144, Georgia

  • Site 584

    Kutaisi, 4600, Georgia

  • Site 586

    Tbilisi, 0144, Georgia

  • Site 634

    Athens, 106 76, Greece

  • Site 731

    Warsaw, 04-501, Poland

  • Site 736

    Rzeszów, 35-326, Poland

  • Site 738

    Wroclaw, 52-416, Poland

  • Site 752

    Tychy, 43-100, Poland

  • Site 754

    Warsaw, 02-172, Poland

  • Site 802

    Belgrade, 11000, Serbia

  • Study Site 002

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.